Short answer
LEMAITRE VASCULAR INC (LMAT) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Filing contains only forward-looking statement disclaimers, not reported financial results.
LEMAITRE VASCULAR INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Filing contains only forward-looking statement disclaimers, not reported financial results
- Investors should review the referenced earnings exhibit for fiscal-year 2026 performance and guidance
- Management highlights material execution risks identified in its latest Form 10-K and subsequent SEC filings
Item EX-99.1 · Exhibit EX-99.1
- Q2 sales $70.4mm, up 10% organically, with organic growth reaching 12% excluding catheters
- Gross margin expanded 210 bps to 72.1%; operating income rose 26% to $20.4mm
- Artegraft sales increased 34%; product approved in 56 countries and represented 21% of sales
- Full-year guidance midpoint: sales $276.3mm, operating income $76.8mm, EPS $2.89
- $376.2mm cash supports international warehouse expansion, while $0.25/share dividend and $100.0mm repurchase authorization enhance shareholder returns
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LEMAITRE VASCULAR INC 8-K filings
Get the next LMAT 8-K as it lands
Follow LMAT for push alerts, or ask the research agent what this filing means.